Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

BACKGROUND: Axitinib is an orally active and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-naïve patients with advanced/metastatic (stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondarenko, Igor M, Ingrosso, Antonella, Bycott, Paul, Kim, Sinil, Cebotaru, Cristina L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424571/
https://www.ncbi.nlm.nih.gov/pubmed/25929582
http://dx.doi.org/10.1186/s12885-015-1350-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424571/
https://www.ncbi.nlm.nih.gov/pubmed/25929582
http://dx.doi.org/10.1186/s12885-015-1350-6

Ejemplares similares